MedTrace Logo

Study of SLN12140 in Healthy Adult Participants

NCT06945445 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-04-25

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled phase I clinical study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SLN12140 in healthy participants with single subcutaneous/intravenous dose escalation and multiple subcutaneous administrations

Conditions

  • Healthy Volunteer

Interventions

DRUG

SLN12140

SLN12140 for sc injection or IV infusion

OTHER

Placebo

Placebo for sc injection or IV infusion

Sponsors & Collaborators

  • Linno Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Jing Zhang, Doctor of Pharmacy · Huashan Hospital

  • Xiaojie Wu, Doctor of Pharmacy · Huashan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Days
Max Age
65 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2026-05-31
Completion
2026-06-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06945445 on ClinicalTrials.gov